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Summary: The procedures available for determination of clobazam (Frisium, Hoechst) are gas Chromatography,
fluorometry, and thin-layer Chromatography. The study presents detailed descriptions of analytical procedures
appropriate for routine determinations in serum and urine, and results from human trials. Moreover, the physico-
chemical properties of clobazam, viz., solubility, distribution, and protein binding are given.
Bestimmung von Clobazam in Serum und Urin mittels Gaschromatographie, Dünnschichtchromatographie und
Fluorometrie
Zusammenfassung: Die vorliegende Arbeit gibt eine ausführliche Beschreibung von gaschromatographischen, dünn-
schichtchromatographischen und fluorometrischen Anälysenmethoden zur routinemäßigen Bestimmung von Cloba-
zam (Frisium, Hoechst) und seinen wichtigsten Metaboliten in Serum und Urin. Es werden Ergebnisse von Untersu-
chungen am Menschen präsentiert und darüber hinaus Angaben zu folgenden physikalisch-chemischen Eigenschaften
des Präparats gemacht: Löslichkeit, Verteilung und Protein-Bindung.
Introduction
Methods are described for the determination of the new
anxiolytic agent clobazam1) (a 1,5-benzodiazepine (1))
in serum (gas Chromatography and fluorometry) and
urine (thin-layer-chromatography). Clinically relevant
physico-chemical data are also presented.
Clobazam
Reagents
Ethyl ether, ethyl acetate, both reagent grade; internal standard:
1 mg/1 diazepam in demineralized water.
Equipment
Glass stoppered centrifuge tubes volume about 10 ml: glass
stoppered test tubes with tapered end after Beckett; Vortex
mixer; refrigerating centrifuge; gas Chromatograph; integrator
HP 3380.
Processing
To 1 ml serum in a centrifuge tube add 0.1 ml of the internal
standard solution, and mix with 5 ml ethyl ether on a Vortex
mixer for 30 s. Centrifuge for 5 min in a refrigerating centrifuge
at 0-5°C, transfer about 4 ml of the organic phase to a Beckett
tube, and evaporate to dryness at about 40 °C under nitrogen
flow. Take up the residue with 50 \ ethyl acetate, and keep in a
refrigerator until analysis.
Gaschromatographic Determination in Serum
Clobazam and its main metabolite in serum, N-des-
methylclobazam, are determined by gas Chromatography
using procedure akeady described for 1,4abenzpdia^
zepines (2-4).
*) Frisium®, Hoechst Aktiengesellschaft.
Gas-chromatography
Apparatus:
Column:
Stationary phase:
Temperature:
Hewlett-Packard 5700 with nitrogen-specific
FID 18 789 A and glass-jet
Glass column 1.20 m X 4 mm
2% OV 101 on Chromosorb W/AW-DMCS,
120-150
Oven: 240 °C isothermal
Injection port: 300 °C
Detector: 300 °C
0340-076X/80/0018-0209S2.00
© by Walter de Gruyter & Co. · Berlin - New York
210 Hajdu, Uihlein and Damm: Determination of clobazam in serum and urine
Carrier gas: Helium
Flow rate: 40 ml/min
Sample volume applied:
1-2 μΐ
Duration of analysis:
about 6 min
Figure 1 shows the chromatograms of a serum blank, a
serum blank with the addition of 0.05 mg/1 of clobazam
and N-desmethylclobazam, and a patient's serum cont-
aining 0.2 mg/1 clobazam and 0.11 mg/1 N-desmethyl-
clobazam. Evaluation was carried out with the integrator
by an internal standard procedure, in which the peak
areas of the compounds to be determined are compared
with the peak area of diazepam.
Evaluation may also be performed by comparing the
corresponding peak heights in the chromatogram. The
linearity of this evaluation method was verified with
mixtures of the pure compounds in ethyl acetate in
the range 1 to 25 ng injected (r = 0.9992).
Precision and accuracy
Mixtures of clobazam and N-desmethylclobazam were diluted
in serum. The serum samples were split in order to obtain six
identical dilution series.
These series were analysed consecutively and gave the
following results (tab. 1).
Tab. 1. Gas-chromatographic determination of clobazam and
N-desmethylclobazam in serum.
Added Found
(mg/1) Clobazam
(mg/1)
N-Desmethylclobazam
mg/1
0.5
0.2
0.1
0.05
0.02
0.01
0.51 ±
0.21 ±
0.100 ±
0.055 ±
0.019 ±
0.01 1±
0.012
0.008
0.0033
0.0026
0.0008
0.0010
(2.4%)
(3.8%)
(3.3%)
(4.7%)
(4.2%)
(9.1%)
0.53
0.21
0.091
0.052
0.020
-
± 0.016
± 0.028
± 0.009
± 0.009
± 0.002
-
( 3.0%)
(13.0%)
( 9.9%)
(17.3%)
(10.0%)
-
Blank* 0.007 ± 0.0017
Bias + 0.004 ± 0.005 mg/1 + 0.007 ± 0.015 mg/1
*The blank value was obtained from a compound interfering
with clobazam (retention time = 3.59 min versus 3.52 min for
clobazam) As the separation of these compounds is extremely
difficult and the blank value is only in the order of magnitude of
the detection limit, we suggest a correction of the results.
For clobazam, the relative error of the method increases
with decreasing values, which is usually the case in Chro-
matographie trace determinations. The absolute errors
correlate well and form a straight line, which does not
go through the origin. This permits us to describe the
error of the method as the sum of a constant and
relative error. Thus, the precision of the method cal-
culated for clobazam amounts to 0.002 ing/1 + 2.2% of
the value measured.
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Fig. 1. Determination of clobazam and N-desmethylclobazam in serum by gas chrpmatography.
a) Serum blank
b) Admixture of 0.05 mg/1 each to serum blank
c) Serum levels after 5th administration of clobazam
Glass column 1.2 m χ 4 mm 2% OV 101 on chromosorb W/AW-DMCS 240 °C isothermal.
1: Internal standard
C: Clobazam
N: N-desmethylclobazam
U: Unknown
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Although the above-mentioned correlation is not satis-
factory for N-desmethylclobazam, we prefer to describe
the error dependency in the same way, resulting in
0.006 mg/1 + 2.5 % of the value measured.
The precision of the method thus obtained enables the
limit of detection for quantitative determinations to be
easily assessed. If the limit of detection is defined as
tp χ S. D. (the concentration being 0), the following
values are obtained: (n = 6, ΐρ:0.ο5 = 2.06)
0.005 mg/1 for clobazam
0.015 mg/1 for N-desmethylclobazam
Selectivity
The method measures clobazam and N-desmethylcloba-
zam selectively. The determination of N-desmethyl-
clobazam in therapeutical levels is only possible if a
glass column and FID with glass-jet are used. The
following synthesized polar metabolites can certainly
not be detected in therapeutical levels:
4'-hydroxyclobazam
4/-(3/)-hydroxy-3'(4/)-methoxyclobazam
4'-hy droxy-N-desme thy Iclobazam
4'-(3/)-hydroxy-3/(4/)-methoxy-N-desmethyl-
clobazam
Results obtained from a multiple-dose human
study
In a human study, clobazam was administered to seven volun-
teer test persons for 10 days daily at 9 a.m. in a dose of 10 mg
and at 7 p.m. in a dose of 20 mg. The blood samples were taken
repeatedly on the first day, and before each administration on
the following days. (5).
On the first day, the maximum serum level of clobazam
(0.31 mg/1) was reached two hours after the admini-
stration. The elimination half-life was eight hours.
N-desmethylclobazam was detected in the blood not
earlier than eight hours after administration in a con-
centration of only 0.05 mg/1.
On the fourth day of treatment, the clobazam levels
reached a steady state of 0.90 ± 0.23 mg/1. N-des-
methylclobazam which had a half-life of 50 hours
reached a steady state approximately on the 9th day
of treatment at serum levels of 3.6 ± 1.3 mg/1. An
example for the course of serum levels is shown iri
figure 2.
Fluorometric Determination in Serum
Clobazam can also be determined by fluorometry. It
does not show native fluorescence, but can be trans-
forme d into a fluorophore by irradiation with short-
wave UV light (6). The advantage of the method is
that it is independent of a blank value as the sample
is measured before and after irradiation. This trans-
formation shows goodreproducibiliity (ef. I.e. (7)).
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Fig. 2. Concentrations in human serum following multiple dose of
clobazam (30 mg/day).
• clobazam
ο N-desmethylclobazam
Reagents
Ethyl ether, ethyl alcohol, both reagent grade; Standard
solution: 0.5 mg/1 clobazam in ethyl alcohol.
Equipment
Glass stoppered centrifuge tubes, volume about 10 ml;
Vortex mixer; centrifuge; Pen-Ray lamp 11 Sc 1 (Ultra-
Violet Products, Inc., San Gabriel, California); irradiation
chamber with two 1 cm cells; fluorometer Perkin Elmer
MPF3.
Processing
To 1 ml serum in a centrifuge tube add 5 ml ethyl ether, and
shake for 30 s on a Vortex mixer. Centrifuge briefly, pipet off
4 ml from the supernatant ether phase into a test tube, and
evaporate to dry ness at about 40 °C under nitrogen flow. Take
up the residue with 2 ml ethyl alcohol (sample solution) and
keep protected from light until fluorometric measurement.
Fluorometric measurement
Adjustment:
Excitation wavelength
Excitation slit
Emission wavelength
Emission slit
Sample sensitivity
364 nm
3nm
400 nm
6 nm
30
Calibration:
In the irradiation chamber, irradiate 2 ml standard
solution with UV light in a 1 cm cell for about one
minute. The irradiation time depends on the intensity
of the lamp and has to be readjusted from time to time.
Adjust the scale reading obtained from the irradiated
standard solution to 100% amplitude by means of the
sample adjust button. This adjustment remains unchanged
during sample measurement.
Fill the sample solution into a cell and measure (value 1). Sub-
sequently, irradiate the sample solution for exactly the same
time as the standard solution and measure again (value 2).
Value 1 (non-irradiated solution) is regarded as blank value and
subtracted from value 2 prior tp calculation. Calibration curves
are established with sera containing standard quantities of the
compound. Calibration is linear up to a concentration of 5 mg/1.
Precision and limit of detection
The data (tab. 2) show a constant precision of the method
of 0.016 mg/1 within the concentration range 0.1 to 1.0
mg/1 serum. Consequently, the limit of detection (cf.
paragraph oil gas chromatography) is 0.04 mg/1.
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Tab. 2. Results obtained from admixtures to serum.
Added
(mg/1)
0.1
0.2
0.3
0.4
0.5
0.6
0.8
1.0
Found
(mg/1)
0.098 ± 0.013
0.200 ± 0.017
0.310 ±0.020
0.405 ± 0.013
0.500 ± 0.016
0.596 ± 0.023
0.794 ± 0.018
1.005 ± 0.010
n
5
15
5
15
5
10
10
10
Blank value
Bias
0 ± 0.006
+ 0.001 ± 0.005 mg/1
17
Selectivity
We examined whether the metabolites mentioned above
show fluorescence under the same conditions as cloba-
zam: the fluorescence of N-desmethylclobazam amounts
only to one third of that of clobazam. 4'-Hydroxyclobazam
and 4'hydroxy-N-desmethylclobazam show one tenth of
the fluorescence of clobazam. The two hydroxy-methöxy
metabolites show no fluorescence. 1,4:Benzodiazepines do
not interfere with the method.
Although the fluorometric method is less specific than
gas chromatography, it is a useful alternative for single-
dose serum kinetics (cf. next paragraph), where these
metabolites are only found in negligible serum concen-
trations (8). Stewart et al. showed (7) that the selectivity
can be improved by using hexane as extraction agent.
Comparison of the methods
The quality of both methods is best demonstrated by
parallel determinations in human trials. The results ob-
tained from parallel determinations performed 0 to 24
hours after administration to 10 test persons correlate
well (cf. fig.3);
n = 60
r = 0.967
CGC = 0.96 X CF1 + 0.015 mg/1
Sy.x = Sx.y = 0.042 mg/1
It should be mentioned that this correlation exclusively
refers to clobazam, because N-desmethylclobazam was
found only in negligible amounts.
Thin-layer Chromatographie determination in urine
Clobazam and the main metabolites in man, dog, and
monkey - N-desmethylclobazam, 4'-hydroxyclobazam,
and 4'-hydroxy-N-desmethylclobazam — can also be
quantitatively determined by thin-layer chromatography.
The compounds are easily separated on silica gel, using
the mobile phase chloroform/n-heptane/methanol
(85 ml + 10 ml + 5 ml). Quantitative evaluation is carried
0.1 Q2 0.3 0.4
c(Fluorometry) [mg/l]
0.6
Fig. 3. Correlation of concentrations of clobazam in human
serum obtained by gas chromatography and fluorometry.
put by reflectance measurement with the usual TLC
evaluating devices (densitometers) at 230 nm.
As a large amount of the metabolites is excreted as
conjugates (8), the urine has to be treated with glu-
curonidase before determination.
Reagents
Ethyl acetate, chloroform, w-heptane, methanol, all reagent
grade; acetate buffer pH 5.5 (24 g CH3COONa - 3 H2O +
240 ml 0.1 mol/1 acetic acid/1 H20); phosphate buffer
pH 7.5 (15.3 g Na2HPO4 · 2H2O + 1.9 g KH2PO4/1 H2O
saturated with NaCl); 0.01 mol/1 sodium hydroxide solution;
0.01 mol/1 hydrochloric acid; 0-glucurpnidase (Boehringer,
Mannheim); ready-prepared TLC plates Si 60 F2-54 20 X 20 cm
(silica gel with fluorescence indicator, E. Merck, Darmstadt)
Equipment
Glass stoppered centrifuge tubes, volume about 10 ml; Vortex
mixer; water bath; centrifuge; Desaga mobile phase trough;
Desaga aütöspotter; TLC^spectrophotometer PMQII with micro-
optics (Carl Zeiss); recorder Servogor 310.
Processing
a) Free compounds
To 1 ml urine in a centrifuge tube add 1 ml phosphate buffer
pH 7.5, and mix with 5 ml ethyl acetate on a Vortex mixer for
30 s. Centrifuge for 5 min at 4,000 rpm, transfer about 4.5 ml
of the organic phase to a centrifuge tube, treat with 1 ml 0,01
mol/1 NaOH, and shake again on a Vortex mixer for 30 s. Centri-
fuge, discard the (lower) aqueous layer, and treat about 4.2 ml of
the organic phase with 1 ml 0.01 mol/1 HC1 in the same way.
Subsequently, evaporate 4 ml of the organic phase at about
40°C under nitrogen flow. Take up the residue with 100 !
methanol before application.
b) Conjugated compounds
Treat 1 ml urine in a centrifuge tube with 1 ml acetate buffer
pH 5.5 and 5 ml ethyl acetate on a Vortex mixer for 30 s in
order to separate the free compounds. Extract again with 5 ml
ethyl acetate. Treat the remaining aqueous phase2) with 10
2
 Addition of calibration compounds is made at this stage,
since the appropriate glucuronides are not available"/
J. Clin. Chem. Clin. Biochem, / Vol. 18, 1980 / No. 4
Hajdu, Uihlein and Damm: Determination of clobazam in serum and urine 213
0-glucuronidase, and digest at 37°C in a water bath for 48 h.
Subsequently add 1 ml phosphate buffer pH 7,5 and proceed
as described under "Free compounds".
Application and development
The autospotter is able to apply up to 20 samples simultaneously
onto a TLC plate, whereby optimal adjustment secures minimal
spot size.
Apply onto a plate 14 extracts of samples to be measured, 5
extracts of known admixtures, and a sample of pure substance.
Adjustment:
Application speed 3
Heating 3
Ventilation 3 *
Application volume 5 Ο μΐ
The plates are developed simultaneously in a mobile phase of
chloroform/w-heptane/methanol (85 ml + 15 ml + 5 ml) at room
temperature.
Length of run: 16 cm
Development time: about 100 min
Rf values:
Clobazam 0.90
N^Desmethylclobazam 0.5 9
4'-Hydroxy clobazam 0.48
4'-Hydroxy-N-desmethyldobazam 0.31
Measurement
Adjustment of TLC spectrophotometer PMQII:
Slit length 2 mm, slit width 14 mm (equivalent to 0.5 X
3.5 mm with microoptics)
Wavelength 230 nm
Speed of plate reck 30 mm/min
Adjust the plate reck to the first substance spot and scan the
plate within the corresponding Rf range.
Evaluation
Evaluation on the basis of the peak areas is done by hand or by
means of an integrator. For each plate, the calibration is cal-
culated separately from admixtures to urine. Linearity is secured
up to a concentration of 1 mg/1 urine. At higher concentrations,
either less urine is used or a smaller aliquot is applied onto the
plate.
Results from addition of standard substances to
urine
Since the original substance is not found in urine (6),
only the metabolites were added. These dilutions were
split into 21 identical samples arid processed as described
for free and conjugated compounds. The following
results were obtained (tab. 3).
Free compounds
Precision for all three metabolites is 0.025 mg/1 + 4%
of value. The limit of detection calculated from this is
0.05 mg/1 (c. f. paragraph on gas chromatography).
Conjugated compounds
Precision Detection
limit
N^desmethylr 0.035 mg/1 + 3 % of value 0.07 mg/1
clobazam
4'-Hydroxy- 0.065 mg/1 + 1.4%-of value 0.13 mg/1
clobazam
4'-Hy droxy- 0.025 mg/1 + 2% of value 0.05 mg/1
N-desmethyl-
clobazam
Tab. 3. Thin-layer Chromatographie determination of metabolites
of clobazam in urine.
Added
(mg/1)
Found
N-Desmethyl-
clobazam
(mg/1)
4'-Hydroxy-
clobazam
(mg/1)
4'-Hydroxy-N-
desmethylclo-
bazam (mg/1)
a) Processed as free compounds
1.0
0.5
0.2
0.1
0.99 ± 0.06
0.48 ± 0.05
0.20 ± 0.05
0.09 ± 0.01
1.00 ± 0.06
0.51 ±0.05
0.22 ± 0.03
0.10 ± 0.02
0.99 ± 0.06
0.5 3 ±0.06
0.24 ± 0.03
0.09 ± 0.03
Bias -0.01 ±0.01 +0.01 ±0.01 +0.01 ±0.03
b) Processed as conjugated compounds
2.0
1.0
0.5
0.2
0.1
Bias
2.00 ± 0.06
1.01 ± o.06
0.53 ± 0.04
0.18 ± 0.03
0.09 ± 0.02
1.96 ± 0.09
1.08 ± 0.09
0.56 ± 0.08
0.28 ± 0.07
0.12 ± 0.06
1.96 ± 0.09
1.03 ± 0.07
0.53 ± 0.07
0.20 ± 0.03
0.09 ± 0.03
±0.02 +0.04 ±0.05 0 ± 0.03
Figure 4 shows the cumulative urinary excretion of the
conjugated metabolites after a single oral dose of 40 mg
clobazam given to a healthy volunteer.
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Fig. 4. Cumulative excretion in urine after a single dose of 40 mg
clobazam.
Subj. no. 1
N-desmethylclobazam
ο ο ΑΟ = 0.032 Kl = 2.130
K2= 0.360 TO =0.019
4'-hydroxy clobazam
χ χ AO = 0.017 Kl = 4.063
K2= 0.099 TO = 0.001
4'-hy droxy-N-desmethylclobazam
.—· AO = 0.038 Kl = 1.767
K2= 0.206 TO = 0.001
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Physico-Chemical Data of Clobazam
Besides the determination methods, the following pro-
perties are of clinical interest:
UV absorption spectrum
The UV spectrum (fig. 5) was taken with a recording
spectrophotometer (Beckman Acta M VI) at a concen-
tration of 10 mg/1 in ethanol. It shows a maximum at
228 nm (Ajf^1 = 1450) and a weak double maximum
at 285 and 295 nm (A}!™11 = 75)."
Solubility
The solubility in water is 80 mg/1 within the pH range
3 to 11.
250 300
Xlnrn]
350
Distribution
The compound is freely soluble in lipids. Aqueous buffers
containing 5 mg/1 of clobazam and N-desmethylclobazam
(5 mg/1) were extracted with pctanol. Within the pH
range 1.2 to 12.4, both compounds were found practically
quantitatively in the organic phase at the distribution
equilibrium.
Protein binding
Protein binding of the compound was determined by
equilibrium dialysis according to Scholtan(9). Solutions
of 0.125—2.0 mg/1 clobazam in human serum were
diälyzed against 0.067 mol/1 phosphate buffer pH 7 at
room temperature overnight. At equilibrium clobazam
was determined fluorometrically in serum and the
corresponding buffer solutions. The adsorption iso-
therm after Freundlich (cf. fig. 6) gave the following
equation:
log Cbound = 0.925 X log cfree + 0.780 ± 0.045
i.e., 85 to 90 percent clobazam is bound to serum protein
at therapeutical levels (0.1-1.6 mg/1). Similar results
were obtained with ultracentrifugation (Centriflo mem-
brane cones from Amieon, Lexington, Mass./USA).
0.2
- 0.1
0.01
0.1
Abound 'fmg/U
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Fig. 5. Absorption spectrum of clobazam (10 mg/1 in ethanol)
1 cm optical pathway.
Fig. 6. Protein-binding of clobazam in human serum,
r = 0.996
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